In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucrative Conference: Benda Recognizes $1.3 Million For Gendicine Order

This article was originally published in PharmAsia News

Executive Summary

SHANGAHI - Benda has recognized $1.3 million in revenues from an order worth $3.8 million placed at a recent conference for its cancer gene therapy Gendicine, the company announced Dec 5

You may also be interested in...



Chinese Pharma Benda Reports 66 Percent Increase In Revenue For 2007

SHANGHAI - Benda Pharmaceutical announced a jump in profits for the fourth quarter and fiscal year ended December 31, 2007, mainly due to SiBiono's gross profits of $5.27 million, which Benda acquired in April 2007

Chinese Pharma Benda Reports 66 Percent Increase In Revenue For 2007

SHANGHAI - Benda Pharmaceutical announced a jump in profits for the fourth quarter and fiscal year ended December 31, 2007, mainly due to SiBiono's gross profits of $5.27 million, which Benda acquired in April 2007

Benda’s Jiangling Plant Gets Production Approval

SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22

Related Content

UsernamePublicRestriction

Register

SC065873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel